No Data
Performance Highlights | Sinwi Medical-B (6609.HK): Profit turning point is approaching, overseas layout is gradually showing results.
On September 2nd, China's neurointerventional medical device pioneer, Xinwei Medical (6609.HK), which is listed in Hong Kong, held its 2024 interim performance conference and provided detailed explanations of the company's performance in the first half of this year. The key points of Xinwei Medical's 2024 interim performance are as follows: steady revenue growth, approaching the breakeven point. From the core financial indicators, in the first half of the year, the company achieved revenue of 0.128 billion yuan, a year-on-year growth of 17.24%, demonstrating a steady growth trend and reflecting its strong market adaptability and business resilience in the face of complex and volatile financial market conditions and multiple challenges such as centralized procurement policies, which lay the foundation for the company's future development.
Xinwei Medical-B (06609) releases mid-term performance: gross profit of 82.281 million yuan, an increase of 3.22% year-on-year.
Xinwei Medical -B (06609) released the interim performance for the six months ending on June 30, 2024, the group...
Express News | Shanghai HeartCare Medical Technology H1 Gross Margin 64%
Express News | Shanghai HeartCare Medical Technology H1 Gross Profit RMB 82.3 Million
Express News | Shanghai HeartCare Medical Technology H1 Capex RMB 1.4 Million
Express News | Shanghai HeartCare Medical Technology H1 Revenue RMB 128.5 Million
No Data
